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reporting within person randomised trials
 OPEN ACCESS
Evidence shows that the quality of reporting of randomised controlled trials (RCTs) is not optimal.
The lack of transparent reporting impedes readers from judging the reliability and validity of trial
findings and researchers from extracting information for systematic reviews and results in research
waste. The Consolidated Standards of Reporting Trials (CONSORT) statement was developed to
improve the reporting of RCTs. Within person trials are used for conditions that can affect two or
more body sites, and are a useful and efficient tool because the comparisons between interventions
are within people. Such trials are most commonly conducted in ophthalmology, dentistry, and
dermatology. The reporting of within person trials has, however, been variable and incomplete,
hindering their use in clinical decision making and by future researchers. This document presents
the CONSORT extension to within person trials. It aims to facilitate the reporting of these trials. It
extends 16 items of the CONSORT 2010 checklist and introduces a modified flowchart and baseline
table to enhance transparency. Examples of good reporting and evidence based rationale for
CONSORT within person checklist items are provided.
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Introduction
Many journals now require that reports of randomised controlled
trials (RCTs) conform to the recommendations in the
Consolidated Standards of Reporting Trials (CONSORT)
statement.1 The CONSORT statement includes a checklist of
items that should be included in the trial report. The most recent
version of the checklist was published in 2010.1 These items
are based on evidence whenever possible. The statement also
recommends including a flow diagram to show the flow of
participants from before enrolment to final analysis. Explanation
and elaboration of the rationale for checklist items is provided
elsewhere.2
The primary focus of the CONSORT statement is the most
common type of RCT, with two treatment groups using an
individually randomised parallel group design.2 Almost all
elements of the CONSORT statement apply equally to RCTs
with other designs, but some elements need adaptation, and in
some cases additional matters need to be discussed. Members
of the CONSORT group have published several extension
papers3-9 that augment the CONSORT statement. Extensions of
CONSORT 2010 to different trial designs have been published
for cluster randomised trials,10 non-inferiority and equivalence
trials,11 and N-of-1 trials.12 As part of that series, in this paper
we extend the CONSORT 2010 recommendations to RCTs in
which participants receive two or more treatments to different
body sites.
In some RCTs the unit of randomisation is not the individual
person but an organ, such as an eye, or other body site, such as
a venous ulcer.13 These RCTs do not have a generally accepted
name, although some specialties have specific terms; for
example, a “split mouth” design is used in oral health,
“contralateral” study in ophthalmology, and “split face” or “split
body” in dermatology. To encompass all possible medical
specialties, we call these trials “within person” randomised
trials. They are not to be confused with trials in which
randomisation and treatment are at the participant level, with
multiple organs or body sites contributing to the outcome
assessment. These are a type of cluster randomised trial that is
discussed elsewhere.10 Within person trial designs have some
similarities with N-of-1 and crossover trials. Within person trials
differ from crossover trials, however, because the interventions
are delivered at the body site level rather than the patient level.
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This extension will not cover N-of-1 and crossover trial designs;
a specific CONSORT extension for N-of-1 trials has already
been published,12 and an extension is under development for
crossover trials.
Scope of this paper
Within person randomised trials present some particular
challenges. One problem is the potential for a “carry across
effect,” whereby, for example, an intervention applied to one
eye or in an area of the mouth can affects the other eye,
systemically,14 or other areas of the mouth, locally.15 16 Success
or failure of the first replacement hip in a patient requiring
bilateral hip replacement can affect the success or failure of the
second hip operation.17 A related problem is the possibility of
participants dropping out of the trial if the two interventions are
not applied concurrently.
In the simplest within person randomised trials two interventions
(one of which may be a control or usual care) are applied to
each participant at two separate body sites, either concurrently
or sequentially. More complicated designs include trials with
more than two interventions, more than two sites within the
same participants, and a mixture of patients with bilateral and
unilateral disease.
Here, we summarise the key methodological features of within
person randomised trials. We consider the empirical evidence
about how common such trials are and summarise published
studies of the quality of reporting of such trials. Following these
literature reviews, we make suggestions for additions and
amendments to the CONSORT checklist adapted for within
person RCTs and give examples of good reporting. This
guideline will focus on the simplest form of the within person
randomised trial where all participants receive two interventions,
with each intervention applied to one of the two randomised
sites. Most of the recommendations also apply to the more
complicated designs, and we discuss some specific issues later
in this paper.
Methodological features of within person
randomised trials
Design
In a within person trial treatments are randomly assigned to two
organs, body parts, or body sites, such as arms, eyes, or breasts,
or to two sites of a single organ, body part, or body site, such
as teeth or sides of the mouth, warts, burns, or bedsores. Key
design questions for within person trials are shown in box 1.
A crucial question is whether the within person design is suitable
for the circumstances. It is appropriate for conditions that occur
in at least two body sites within the same person, if the stage of
the condition or disease is similar in the sites to be randomised,
and for treatments that can be tested locally without influencing
the outcome on the matching site—that is, without carry across
effect. When the interventions are not applied simultaneously,
the participant’s condition should have underlying stability.
Surgical wound closure and tendon repair, for example, are
non-stable conditions that require a concurrent design.
The carry across effect has been of concern in trials using within
person designs in several specialties.14-17 It can lead to bias and
tends to dilute the treatment effect. It is similar to the temporal
carry over effect in crossover trials, in which lingering effects
of the first intervention may require adjustment for different
baselines before the second intervention or the use of wash-out
periods (which are more difficult to handle in a within person
trial). A within person design is unlikely to be appropriate if
there is an expectation of a substantial carry across effect.
Sequential and concurrent treatment
In a within person trial, the interventions can be applied
sequentially or concurrently. The sequential approach is common
in trials in which it is either undesirable or infeasible to
administer the interventions at the same time. Examples are
bilateral hand surgeries that render the patient unable to perform
basic activities of daily living and bilateral eye interventions
that would render the patient without functional vision for an
unacceptable period of time.
Concurrent treatments can be applied when they do not
substantially affect participants’ lives (for example, for skin
conditions) or where the natural history of the disease might
change too drastically in the time between interventions if
applied sequentially. With concurrent treatment, loss to
follow-up will automatically be matched across treatment arms,
but harms (unintended effects) may be difficult to attribute to
a specific treatment. Another concern in concurrent treatment
trials is the potential for confusion as to which site receives
which treatment, particularly when there is a long treatment
period. Traditional methods for monitoring compliance might
be insufficient in within person trials when the participant is
responsible for administering the treatment.
Sample size
As with crossover and cluster trials, an efficient sample size
calculation requires an estimate of a correlation coefficient. For
within person trials the expected within person correlation of
outcomes with the two treatment options must be incorporated
into the sample size estimation. In practice, for many trials it is
unlikely that there will be data to support a realistic estimate of
this value, yet ignoring it is likely to result in an overestimation
of the sample size. Some attempt to estimate a correlation
coefficient is desirable.
Key questions relating to sample size thus include whether the
sample size calculation should take into account the expected
within person correlation of outcomes, and, if so, how will this
correlation coefficient be estimated. And how sensitive the
sample size calculation is to deviations from the postulated
correlation coefficient.
Analysis
Appropriate statistical methods that consider the correlation
between sites should be used. These methods can be quite
simple, such as a paired t test. Other considerations include
losses to follow-up and handling of missing data, which can
include both sites in each participant or just a single site.
In concurrent trials, when harms affect participants in a way
that is not specific to a site, such as headache or nausea,
attributing the symptom to a specific intervention can be difficult
or impossible.
How common are within person
randomised trials?
Because no common terminology exists for within person
randomised trials, they are difficult to identify using traditional
electronic search methods.
A PubMed sample of 1360 randomised controlled trials
published in 2012 found that 24 (1.8%) were labelled as “split
body” or used a within person design (D Altman, personal
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Box 1: Key design questions for within person trials
Is the within person design appropriate (ie, carry across effects are unlikely)?
Will the treatments be administered concurrently or sequentially?
Are the sites for each participant similar in terms of baseline characteristics such as location, anatomy (eg, tooth type), and severity of
disease?
If treatments are given sequentially will baseline information be recorded at the time of randomisation or at the time of treatment
administration?
How will the order of treatments and allocation to body sites be determined (eg, right versus left)?
Will there be any provision to monitor that the assigned treatment was actually applied to the correct site?
Will the outcome evaluator be blind (masked) to the treatment assignment of each site, and if so how?
communication). Two earlier samples yielded prevalences of
1.7% (9/519) of trials published in 2000 and 2.6% (16/616) of
trials published in 2006.18 19 Overall, about 2% of published
RCTs seem to use a within person design. Within person
randomised trials are more common in some specialties
(ophthalmology, dentistry, and dermatology), than others
(rheumatology), and apparently not done at all in others
(cardiovascular medicine, hepatology).
A recent study identified 43 split mouth designs in a sample of
413 RCTs (10%) published in eight oral health journals with
high impact factors from 1992 to 2012.20 Another study found
that 67 of 276 (24%) RCTs published between 1989 and 2011
in implant dentistry journals used the split mouth design.21
Lee et al found that 13% (9/69) of a sample of ophthalmology
RCTs had a within person design in which the two eyes of an
individual were randomly assigned different treatments.22
What is the quality of reporting of within
person trials?
Although articles on the quality of reporting of RCTs in relation
to CONSORT are relatively common, only two investigators
have specifically examined the quality of reporting of within
person trials. Lesaffre et al examined the reports of 34 split
mouth studies published in 2004.23 Just over half of the trials
reported an appropriate statistical method for a within person
design, and only 15% included comments on the potential
correlation and treatment carry across effect that could occur
with this study design. To assess quality of reporting, the authors
adapted the checklist for the cluster RCTs extension to the
CONSORT guidelines.10 Overall reporting was poor, with only
41% of split mouth trials reporting the method of random
sequence generation and 26% reporting an allocation
concealment mechanism.
Scherer et al in 2012 found that only 42% of 60 within person
ophthalmology trials reported a rationale for using that design.24
Only 18% reported an adequate method of allocation
concealment, and 52% reported that the person measuring the
outcome was masked. Other studies indicated that most within
person trials do not take into account the within person
correlation in sample size calculations22-26 or in the statistical
analysis.17-28
Methods used to develop this CONSORT
extension
This CONSORT extension was first discussed by Doug Altman,
Diana Elbourne, Bobbi Scherer, and Barbara Hawkins in 2003,
when the main focus was trials in ophthalmology. Subsequently
Bryan Chung expressed an interest from the perspective of hand
surgery. The work did not progress until 2013, when Nikolaos
Pandis raised the matter from the dental perspective, and a
“virtual” group comprising the authors of this paper was
convened in 2013. This group met many times over the
intervening years, mainly by teleconference, with occasional
face-to-face meetings of two or more authors.
CONSORT checklist for within person
RCTs
Initial work on this extension to the CONSORT checklist
preceded the 2010 update of the CONSORT statement but was
mainly conducted between 2013 and 2016. The checklist and
explanatory text were informed by reviews of published
randomised trials (as cited) and completed through
teleconferences over several years. In the absence of any specific
funding we were unable to follow all of the recommended
procedures of the EQUATOR group,29 such as a face-to-face
consensus meeting.
Fig 1⇓ shows the standard CONSORT checklist and our
suggested modifications for within person randomised trials. In
this section we discuss each of these checklist items, explain
the background, and provide one or more examples of good
reporting. We also discuss several checklist items for which we
do not suggest any modification but for which implementation
requires specific considerations for within person RCTs. For
some items there are different considerations for concurrent and
sequentially delivered interventions.
Title and abstract
Item 1a: Title
Standard CONSORT item—Identification as a randomised trial
in the title.
Extension for within person trials—Identification as a within
person randomised trial in the title.
Example 1—“A comparison of anterior and posterior chamber
lenses after cataract extraction in rural Africa: a within patient
randomised trial.”30
Example 2—“Effects of intra-alveolar placement of 0.2%
chlorhexidine bioadhesive gel on dry socket incidence and
postsurgical pain: a double blind split mouth randomised
controlled clinical trial.”31
Example 3—“Randomised, double blind, split face study of
small-gel-particle hyaluronic acid with and without lidocaine
during correction of nasolabial folds.”32
Example 4—“Randomised, double blind, contralateral eye
comparison of myopic LASIK with optimized aspheric or prolate
ablations.”33
Explanation—Identification of the trial as a within person
randomised trial ensures that readers will start thinking of the
implications of the design in relation to sample size and analysis.
We recognise that different terms to describe those designs are
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used depending on the specialty. Terms such as split mouth,
split face, split body and contralateral convey the same within
person design in different specialties and are suitable
alternatives. In addition, it is desirable, even though not
permitted due to length by all journals, to include in the title
information on participants, interventions, comparators, and
outcomes.
A review of split mouth trials published in 2004 showed that
only two of 33 identified the trial as a split mouth in the title.23
A more recent review of published RCTs (1992-2012) in the
eight oral health specialty journals with the highest impact
factors found that only seven of 43 (16%) trials with a split
mouth design identified the trial as split mouth in the title.20
Item 1b: Abstract
Standard CONSORT item—Structured summary of trial design,
methods, results, and conclusions (for specific guidance see
CONSORT for abstracts3).
Extension for within person trials—Specify a within person
design and report all information outlined in table 1⇓.
Example—See fig 2⇓.
Explanation—Clear, transparent, and sufficiently detailed
abstracts are important. Some readers might have access only
to the abstract, and many others will skim it before deciding
whether to read further. A well written abstract also helps
retrieval of relevant reports from electronic databases. In 2008
a CONSORT extension on reporting abstracts was published,3
and those recommendations were incorporated into CONSORT
2010.
Abstracts for within person RCTs should indicate the paired or
within person nature of the trial. Table 1⇓ shows the minimum
information that should be included in the abstract of a within
person trial, in addition to the items recommended for all trials.
We were not able to find examples of good reporting that tackled
all the items required. We therefore developed an example
abstract by enhancing a published abstract (fig 2⇓).
Methods
Item 3a: Trial design
Standard CONSORT item—Description of trial design (such as
parallel, factorial) including allocation ratio.
Extension for within person trials—Rationale for using a within
person design and identification of body sites.
Example 1—“In this study, we present the results of a
contralateral eye study in which patients were randomised to
undergo implantation with either the Tecnis ZM900 silicone
multifocal intraocular lenses (MIOL) or the Tecnis ZMA00
acrylic multifocal IOL [intraocular lens]. Using a contralateral
study model, we are able to reduce many of the variables that
can occur between patient groups.”34
Example 2—“The GDPs recruited children who had caries
affecting pairs of primary molar teeth, which were matched for
tooth type, arch and extent of caries.”35
Explanation—The within person design avoids possible
imbalance between interventions on participant level variables.
The within person design is efficient, because a smaller sample
size is required than for a standard design, and losses to
follow-up are usually equal between treatment groups. However,
carry across effects might reduce efficiency and bias the trial
results—such a design should not be implemented if a carry
across effect is expected. All alternatives must be considered,
and if a within person trial design is used it must be made clear
why it was judged to be the most appropriate and robust design.
The treatment of the body sites can be concurrent or a sequential
(see item 5).
In within person designs baseline characteristics are balanced
at the participant level, but imbalances can occur for site specific
variables, notably severity of disease. The identification and
selection process of the included sites should be described, as
shown in example 2, if applicable.
Item 4a: Eligibility criteria for participants
Standard CONSORT item—Eligibility criteria for participants.
Extension for within person trials—Eligibility criteria for body
sites.
Example—“The inclusion criterion was uncomplicated age
related bilateral cataract with the potential to see 20/40 or better
in each eye. Exclusion criteria were any concurrent medication
apart from ocular lubricants, any coexisting ocular pathology,
unilateral amblyopia, previous intraocular surgery or laser
treatment, retinal complications, pupil dilatation <7 mm, any
surgical complications or inability to co-operate or maintain
follow-up.”36
Explanation—In within person trials two sets of eligibility
criteria are needed: the eligibility of the individual participant
and the eligibility of the body site (such as limb or eye). For
participants to be eligible in a within person design, they must
be able to provide at least two body sites to be treated, one to
receive each intervention. Eligibility criteria for the body sites
should include criteria related to the comparability between sites
within a person.
Item 5: Interventions for each group
Standard CONSORT item—The interventions for each group
with sufficient details to allow replication, including how and
when they were actually administered.
Extension for within person trials—Whether interventions were
given sequentially or concurrently.
Example 1:Concurrent application of interventions—“Patients
were given simultaneous injections of buffered and unbuffered
2% lidocaine with epinephrine 1:100 000. The needles were
inserted simultaneously and the anesthesia was injected for a
20 second count for a total volume of 1.0 ml per injected side.”37
Example 2: Sequential application of interventions—“An
investigator with no clinical involvement in the trial used the
list to prepare directions assigning one of the intraocular lenses
(IOLs) (iMics1 NY-60 IOL or AcrySof SN60WF IOL) for
placement into the patient’s right eye, the first eye to be operated.
The directions for each operation were placed in sequentially
numbered and sealed envelopes. The surgeon opened the
envelopes in sequence on the day of surgery after
hydrodissection and phacoemulsification and implanted the
randomly assigned IOL specified into the patient’s first eye.
The second eye was implanted with the other IOL one week
later.” 38
Explanation—In addition to the standard CONSORT
explanation of detailed reporting of interventions for the
purposes of reproducibility, it is important to describe whether
the intervention was applied to different body sites concurrently
or sequentially. There are several reasons for this. Firstly, the
intervention on one site may dilute the effect on contralateral
site due to potential carry across effect (although ideally trials
with likely carry across effects would not have used a within
person design). Secondly, in sequential designs the time between
interventions might be long, so the baseline state of the untreated
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side might change in the period between interventions. Thirdly,
loss to follow-up is not necessarily balanced in people who did
not receive both interventions concurrently. Measures taken to
avoid a potential carry across effect should be described along
with the reasons for taking these measures.
We recommend that trial authors consult the template for
intervention description and replication (TIDieR) checklist39 for
a list of intervention details that authors should include in their
reports. Authors might also find helpful the CONSORT
extensions for non-pharmacological interventions,7 for herbal
interventions,5 and for acupuncture,4 if applicable.
Item 6a: Outcomes
Standard CONSORT item—Completely defined prespecified
primary and secondary outcome measures, including how and
when they were assessed.
Extension for within person trials—Outcomes should be clearly
defined as per site or per person.
Example 1: Efficacy end points—“The primary efficacy end
point was complete mild actinic keratosis (AK) lesion response
rate per side at week 12. Additionally, lesions that had a
complete response after one session (at week 12) were followed
up until week 24 to observe their maintained response rate.
Complete lesion response rate for all lesions (mild and moderate
lesions) at week 12 was a secondary efficacy end point.”40
Example 2: Safety end points—“The primary safety end point
was the subject’s assessment of maximal pain reported just after
the treatment session at the baseline visit. Secondary safety end
points included the investigator’s local tolerance preference (one
week after baseline session) and incidence of adverse events
(AEs) throughout the study. Also, the investigator performed a
clinical assessment of each lesion achieving complete response
regarding the following signs and symptoms: scarring, atrophy,
induration, redness, or change in pigmentation.” 41
Example 3: Patient preference outcome—“The order of needle
sticks was randomized according to side of the hand (volar vs
dorsal) and order of long fingers (right vs left). All needlesticks
were performed with a standard technique by only two
investigators. Participants were instructed to look away during
the needlesticks. Following both needlesticks they had to rank
the discomfort associated with each needlestick on a scale of 0
(no pain) to 10 (worst pain imaginable). The participant was
then asked to rank ‘which hand they would prefer to receive an
injection in if it was required in the future.’” 41
Example 4: Patient preference outcome—“Preference of the
eyelid warming techniques (eye mask, eye bag, or no preference)
was also recorded after treatment.”42
Explanation—Complete definition of outcomes should include
the timing and method of the measurement. In trials with
concurrent interventions, the timing of outcome measurement
will not differ much from conventional parallel group trials.
Authors should explain how outcomes for each site were
measured independently.
When interventions are sequentially administered, however,
site specific outcome measurements can be made at the same
time after each intervention or simultaneously after the second
intervention. Simultaneous case measurements might be affected
by lag time bias, as the first treated site has a longer recovery
time than the second site, thereby possibly seeming superior (or
inferior) as a result of the time difference. In a randomised trial
this effect is expected to be balanced out across participants
unless there is an interaction between treatment and time, where,
for example, the first site always does better, regardless of
treatment. If such an interaction is expected, however, a
sequential design should be avoided.
In the sequential design pretreatment baseline measurements
might differ in time (before either site being treated) and the
time to when the second site is treated, and this may be
problematic particularly in diseases that might progress or evolve
(eg tumour size, arthritis). The preferred option is to report
baseline values at the time of randomisation; a second option
is to report baseline values at the time of treatment allocation.
It should be clear as to whether these values were similar in
terms of baseline characteristics such as location, anatomy (eg
tooth type) and severity of disease, and the time (at
randomisation or at treatment allocation) when the values chosen
to represent baseline values were recorded.
Investigators should report outcome measurement timing per
site, as well as participant follow-up schedules and should clarify
which value was used in the analysis (eg a six month participant
follow-up or a six month body site follow up).
For any outcomes reported per person, authors should explain
how their measurement is affected by each participant being
exposed to two interventions despite the single measurement
value. Per person outcomes are less relevant for between
treatment comparisons but should be reported as they contribute
to evidence. Participant level outcomes can include those related
to participant’s preferences, harms, and quality of life.
Item 7a: Sample size
Standard CONSORT item—How sample size was determined.
Extension for within person trials—Report the correlation
between body sites.
Example 1—“A sample size calculation was performed based
on the assumptions that the main outcome measurement
(changes in sum score between baseline and end of treatment
on visual analogue scale) is continuous in nature, fairly normally
distributed, and that an additional improvement in the
intervention side of 10 percentage points (standard deviation=15
percentage points) is considered clinically relevant. If the
incidence of the carpal tunnel syndrome on one wrist could be
considered completely independent from the incidence on the
other wrist, 36 independent observations in each group would
be necessary to detect that difference at the 5% level (α=0.05)
with an 80% chance (β=0.2).”43
Example 2—“To estimate sample size for the primary
outcome—pain felt during insertion of the needle and injection
of the anaesthetic according to the VAS [visual analogue
scale]—we took into account the correlation induced by the
paired nature of the data. In a previous trial, the corresponding
SD [standard deviation] in the VAS score could be estimated
at 1.2. Assuming that the SD is equal in the two randomisation
groups and that the correlation between the pain scores for the
same patient in the first and second treatment is 0.6, the
difference in VAS scores would have a SD of 1.10. With a type
I error risk of 0.05, we would need 30 patients to guarantee 80%
power to detect a minimum true difference of 0.6 points in mean
pain experienced during conventional infiltration and
intraosseous anaesthesia.”44
Explanation—A key advantage of the within person design is
the smaller sample size required than for a design in which the
randomisation unit is the participant. This is because each
participant acts as their own control, so the interindividual
variability is reduced, resulting in increased study power and a
decrease in the number of participants required compared with
a study in which participants receive only one intervention.
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For a continuous outcome, the reduction in sample size of using
a within person design compared with a parallel group design
increases as the within person correlation increases. As the
coefficient of correlation (r) gets closer to one, the required
sample size (N) can be dramatically reduced, as indicated by
the following formula45: Npaired=(1−r)Nparallel/2. So for r=0.8,
Npaired/Nparallel is 0.2/2=0.1 (10%). Reported correlation coefficients
in ophthalmology,46 dermatology,47 and orthodontics48 were 0.80,
0.80, and 0.50, respectively. Balk et al49 calculated correlation
coefficients for 811 within group correlation values from 123
studies with 281 study groups. The median within group
correlation value across all studies was 0.59 (interquartile range
0.40-0.81). No heterogeneity of correlation values across
outcome types and clinical domains was observed.49 It is
important that trial authors report the usual quantities required
for sample size calculation, including expected means (and
standard deviations) for each treatment group, significance level,
and power, but also the assumed correlation coefficient as shown
in example 2 and the source of the correlation coefficient used.
In example 1, the sample size calculation was performed without
accounting for the potential correlation between the paired
treatment outcomes. This approach will result in a larger sample
size than if the correlation coefficient between treatment
outcomes is not zero. The correlation coefficient is often not
reported in published within person trials.27
With a binary outcome, not considering the paired nature of the
data will result in a sample size that was the same as for a
non-paired design and is thus conservative. Accounting for the
paired design during sample calculation is complicated. Authors
are encouraged to report if they have taken any steps to account
for the paired design during sample size calculation and to give
appropriate enough details so that for the sample calculation to
be replicated.50
Any allowance in the sample calculation for losses to follow-up
of individuals and or sites should also be reported.
Item 8b: Sequence generation
Standard CONSORT item—Type of randomisation; details of
any restriction (such as blocking and block size).
Extension for within person trials—Methods used to determine
the allocation sequence of body sites and treatments within an
individual (eg how first site to be treated was decided).
Example—“The eye to be operated upon first was selected by
a computer generated table of random numbers by one of the
authors (VV). The second eye underwent cataract surgery after
a gap of at least 2 weeks following surgery in the first eye . . .
Patients were randomized to either receive enoxaparin in the
intraocular infusion fluid (Group I) or not receive enoxaparin
(Group II). The randomization code was allocated inside the
operating room just before the surgery on the first eye. The
second eye received alternate treatment.”51
Explanation—In within person RCTs interventions can be
administered concurrently or sequentially. Randomisation is
used to determine which intervention is applied to which body
site and, in trials with sequential interventions, also to determine
which site is treated first. Thus both how the site to be treated
first was determined and which treatment was administered
should be reported.
In the concurrent approach the two treatments are delivered at
the same time, whereas in the sequential design there is a
“non-trivial” time lag between the two interventions. In both
designs which site will receive what treatment must be
determined. A sensible approach would be to use one random
allocation to determine which site is to be treated first and a
second random allocation for which treatment will be
administered first. Another approach would be to randomise in
a single step to both body site and treatment. Under this scenario
the randomisation list would require the allocation to all possible
combinations of site and treatment, as in a four arm trial: site
one-treatment one, site one-treatment two, site two-treatment
one, and site two-treatment two. The method of minimisation,52
where future allocations are based on previous allocations, with
site and treatment as the factors, would also be suitable.
Item 10: Implementation of randomisation
Standard CONSORT item—Who generated the random
allocation sequence, who enrolled participants, and who assigned
participants to interventions?
Extension for within person trials—replaced by item 10a.
Item 10a: Extension for within person trials: Who generated
the random allocation sequence, who enrolled participants, and
who assigned body sites to interventions.
Example—“The clinical research coordinator for this trial
generated a randomization code with equal numbers (1:1 ratio)
using computer software and assigned each patient to one of
the two groups according to the computer generated
randomization code. The group to which the patients were
assigned was directly communicated by the coordinator to a
member of the operating room staff who prepared the intraocular
lens (IOL). The surgeon was informed about the type of surgery
just before surgery . . . To ensure allocation concealment, the
coordinator kept the assignment schedule until all data were
collected.”53
Explanation—Reporting of how the random sequence was
implemented—specifically, who generated the allocation
sequence, who enrolled participants, and who assigned
participants to trial groups—is recommended. In the given
example only two eyes were available per participant. It is,
however, important to explain how sites were selected when
many were available.
Item 12a: Statistical methods
Standard CONSORT item—Statistical methods used to compare
groups for primary and secondary outcomes.
Extension for within person trials—Statistical methods
appropriate for within person design.
Example 1—“Statistical analyses included the paired t test and
McNemar test. Onset was defined as the time to improve by at
least 1 scale point. A paired Wilcoxon signed rank test was used
to compare the differences in onset of action for
abobotulinumtoxin A and onabotulinumtoxin A.”54
Example 2—“A Wilcoxon sign-rank test was used to compare
treatment and control sides of the nasal cavity for both pain and
discomfort.”55
Explanation—In line with recommendations made by the
International Committee for Medical Journal Editors and the
CONSORT group, analytical methods should be described “with
enough detail to enable a knowledgeable reader with access to
the original data to verify the reported results.”56 Identification
of the within person design and the statistical methods used
allows readers to evaluate the methods of analysis. In examples
1 and 2 a McNemar’s test (proportions) and parametric and
non-parametric tests for matched/within person designs were
applied, which are appropriate.57
When treatments are received sequentially, problems can arise
from carry across effects and a baseline adjustment may be
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required. For example, in split mouth trials baseline values and
failure of dental implants loaded at different time points might
be influenced by the time interval between the two interventions
and the status of the early loaded implant. For example, if the
early loaded implant results in a poor outcome or the time
between operations is long, or both, the patient might rely
excessively on the other side of the mouth, which might be
related to the late loaded implant. This additional burden on the
second implant can have a negative effect on that implant as
well. Conversely, if the outcome in the first implant is good and
the burden on the second implant is small, a satisfactory outcome
in that implant can be more likely. For the sequential design,
baseline values used for the adjustment should be preferably
those collected at the time of randomisation and not at the time
of treatment.
Results
Item 13a: Participant flow (a flow diagram is
strongly recommended)
Standard CONSORT item—For each group, the numbers of
participants who were randomly assigned, received intended
treatment, and were analysed for the primary outcome.
Extension for within person trials—Number of participants and
number of body sites at each stage (fig 3⇓).
Example—see fig 2⇓.
Explanation—The flow diagram is a key element of the
CONSORT Statement and has been widely adopted. For within
person trials it is important to understand the flow of both
participants and body sites. Although we recommend a flow
diagram for communicating the flow of participants and body
sites throughout the study, the exact form and content can vary
in relation to the specific features of a trial.
Item 13b: Losses and exclusions
Standard CONSORT item—For each group, losses and
exclusions after randomisation, together with reasons.
Extension for within person trials—Number of participants and
number of body sites lost or excluded at each stage, with
reasons.
Example—“The 93 subjects enrolled in the study were
considered the Safety Dataset and underwent adverse event
analysis. Twelve of these 93 subjects did not complete the
primary endpoint, non-weight bearing passive flexion, 12
months after surgery. One subject withdrew consent 10 months
after the bilateral surgeries; the withdrawal was unrelated to
either implant. There were two protocol violations in which the
STD [standard] components (femurs with lugs) were not listed
in the study protocol, but the appropriate HF [high flexion]
devices were implanted on the contra-lateral side. One of the
two subjects with a protocol violation had their eligible HF knee
complete the primary endpoint; therefore, that knee was used
in unpaired analyses. There were two revision TKA [Total Knee
Arthroplasty] procedures, one HF device and one STD device.
The HF device was revised six months after the index surgery
and the STD at seven months; both revisions were secondary
to deep infection, and were performed at different centers. The
remaining seven subjects were lost to follow-up, leaving 81
bilateral subjects available for the primary efficacy dataset and
respective analyses and provides a 92.5% (86 of 93) subject
follow-up compliance rate.” 59
Explanation—When interventions are delivered sequentially,
a participant who drops out part way through the trial may have
only one body site assessed for outcome. With concurrent
interventions, when a participant drops out of the trial all
included body sites also drop out. But it is also possible for a
single randomised body site to drop out while the other body
site from the same person remains within the trial. For example,
in a concurrent split mouth design, even though both
interventions are applied to both sites, one site may later drop
out due to an unexpected event such as abscess or an extraction
that does not allow outcome recording on that site. The event
may or may not be related to the intervention.
Authors should indicate the loss of body sites for each
intervention, preferably in the flow diagram.
Item 15: Baseline data
Standard CONSORT item—A table showing baseline
demographic and clinical characteristics for each group.
Extension for within person trials—Baseline characteristics for
body sites and individual participants as applicable.
Example—See table 2⇓.
Explanation—Random assignment by individual person ensures
that any differences in group characteristics at baseline are the
result of chance rather than some systematic bias.61 For within
person randomised trials, the risk of chance imbalance is lower
as all participants receive both interventions, so the baseline
characteristics are identical between groups. But treatment sites
can have different characteristics at baseline. Although important
differences can be controlled for in the analysis, reporting of
baseline values for both the person and the site enables the
reader to judge whether any observed differences owing to
chance might have clinical relevance.
Item 16: Numbers analysed
Standard CONSORT item—For each group, number of
participants (denominator) included in each analysis and whether
the analysis was by original assigned groups.
Extension for within person trials—Number of randomised
body sites in each group included in each analysis.
Example—“Forty five patients with bilateral carpal syndrome
(90 wrists) fulfilled all inclusion criteria; 11 (24%) of these
patients discontinued treatment after randomisation (eight
patients early after randomisation because of non-compliance
in keeping appointments, and three patients because of excessive
pain requiring additional therapeutic measures). Thus 34
patients—that is, 34 actively treated and 34 sham treated
wrists—completed the study . . . Thirty of them (67% of the
initial 45 patients) completed a follow-up at six months.” 43
Explanation—The number of participants and sites that
contribute to the analysis of a trial is essential to interpreting
the results. But the analysis of each outcome might not include
all participants or all participant sites. If participants do not
contribute to the analysis in a within person trial, the
corresponding sites might be lost. One site, however, can
contribute to the data if the other site is lost. Because the sample
size, and hence the power of the study, is calculated on the
assumption that all sites and participants will provide
information, the number of participants and sites contributing
to a particular analysis should be reported so that any potential
drop in statistical power can be assessed. In addition, and as
explained in detail in the CONSORT 2010 guideline,2 it should
be specified whether the analysis was per protocol or
intention-to-treat, with specific details on how the selected
analysis approach was implemented. In the included example
it is not explicitly stated how many wrists were analysed, but
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it is implied that possibly 30 of 45 patients were analysed at six
months.
Item 17a: Outcomes and estimation
Standard CONSORT item—For each primary and secondary
outcome, results for each group, and estimated effect size and
its precision (such as 95% confidence interval).
Extension for within person trials—Observed correlation
between body sites for continuous outcomes and/or and matched
pair tabulation for binary outcomes.
Example 1—See table 3⇓.
Example 2—See table 4⇓.
Example 3—“Thirty-five (65%) of 54 patients reported that the
buffered lidocaine was less painful than the unbuffered lidocaine
on initial injection. Seven patients (13%) distinguished no
difference, and 12 patients (22%) felt less pain with the
unbuffered lidocaine.”37
Explanation—The standard CONSORT guideline should be
followed when reporting the results of within person randomised
trials: point estimates with confidence intervals should be
reported for primary and secondary outcomes. Given the effect
of the within person correlation on the power of the study, the
correlation coefficient for each primary outcome being analysed
should also be provided. However, if the mean difference and
standard deviation of the differences between treatment groups
are reported, then the sample size of a future trial can be
calculated without the need of the correlation coefficient.
For binary outcomes, a presentation using the matched tabulation
format (table 5⇓ and example 2) is desirable, as it allows the
reader to see the concordant and discordant pairs. The matched
tabulation facilitates the use of such trials in future
meta-analyses as it allows using appropriate formulas to adjust
the between treatment variance downwards by accounting for
the within person correlation, even when not explicitly
presented.64-66 Presentation of the 2×2 table of results from a
within person design in a parallel trial format does not allow
for appropriate adjustments of the between treatment variance.66
The paired presentation is also helpful for future sample size
calculations.
Ideally, patient preference outcomes should also be reported at
the participant level, as in example 3.
Item 19: Harms
Standard CONSORT item—All important harms or unintended
effects in each group (for specific guidance see CONSORT for
harms9).
Extension for within person trials—Harms or unintended effects
reported by participant and by body site.
Example 1—“Pimecrolimus cream was generally well tolerated.
No severe adverse events were encountered during the study,
although 20% of patients experienced an adverse event (three
of the 15 patients who completed the study). The most common
side effects were application site reactions (burning, stinging),
which were self limiting. One patient complained of
hyperpigmentation in an initially severely inflamed area, which
was considered to be post inflammatory hyperpigmentation. No
patient reported exacerbation of rosaceiform eruption after the
use of pimecrolimus.” 22
Example 2—“Treatment related adverse events (AEs) occurred
in 41/48 (85.4%) patients. All treatment related AEs were
application site reactions, most commonly irritation. The
majority of AEs were of mild-to-moderate severity. Almost all
treatment related AEs occurred during the split face phase of
the study, with only 11 patients (22.9%) having a treatment
related AE during full face treatment with clindamycin
1%/benzoyl peroxide 5% gel (C/BPO). Three patients developed
severe cutaneous AEs during the split face phase of the study,
all of which subsided during continued treatment, treatment
interruption or dose reduction. One patient discontinued
treatment due to moderate application site irritation. There were
no serious AEs. A post hoc analysis, which was conducted to
determine on which side of the face AEs occurred, indicated
that treatment related AEs, including irritation, dryness, and
erythema, were significantly less common with C/BPO than the
adapalene 0.1%/benzoyl peroxide 2.5% gel (A/BPO) (P≤0.01).”
67
Example 3—“Minor and transient adverse reactions included
herpes simplex virus reactivation (confined to the lips) (one
patient, 3.5%).”68
Explanation—Presentation of harms or unintended effects at
the body site (examples 1 and 2) and at the participant level
(example 3) is important for within person randomised trials.
In concurrent trials in which harms have affected participants
in a way not specific to a site (eg headache, nausea), it will often
be impossible to attribute the symptom to a specific intervention.
In this case no attempt should be made for those outcomes to
be attributed to a particular intervention.
Discussion
Item 20: Limitations
Standard CONSORT item—Trial limitations, addressing sources
of potential bias, imprecision, and, if relevant, multiplicity of
analyses.
Example—“Thirty two patients (23 women, 9 men) were initially
enrolled for the study. Out of those, complete data were available
for 26 patients (18 women, eight men). Two of the remaining
six patients failed to attend for their second side operation. Both
were women who had an open release on one side and reported
complete relief of symptoms at two weeks: both then failed to
attend any further appointments despite repeated reminders.
Another, who reported good relief of her symptoms after a
Knifelights release, refused to have the second side done under
local anaesthesia.”69
Explanation—A limitation of the within person design is that
the treatment of one member of the pair of organs or sites can
affect the other member of the pair, either to improve the
outcome with the other intervention or to suppress the effect.
This carry across effect could potentially render a within person
trial invalid, and such a limitation is unlikely to be reported
given that it would invalidate the trial results. Possible
limitations that should be reported include losses to follow-up
before the second intervention is applied in sequential designs
and mixing up of the interventions, such as which eye gets which
eye drops.
Item 21: Generalisability
Standard CONSORT item—Generalisability (external validity,
applicability) of the trial findings.
Example—“It is also interesting to note that the binocular vision
was not affected by the conjunction of corneal and intraocular
refractive procedures. This seems logical, as ametropias and
accommodative effort were almost symmetrical in both eyes of
the patients, before and after surgery. The visual improvement
had no effect on binocularity; however, this may have been
because the patients in this study had no previous asthenopic
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troubles. Perhaps a different result would have been obtained
if the previous state of binocularity had been more fragile (eg
in high unilateral myopia). Nevertheless, one can remark that
the only patient with previous strabismus had no change in the
postoperative tests. In this study, it has been shown that in
symmetrical myopia, if preoperative binocular vision is correct,
the use of the two different techniques (corneal or intraocular
refractive surgery) on either of the eyes had no effect on
binocularity, and the tremendous difference in keratometry
power was well tolerated.” 70
Explanation—Generalisability refers to the applicability of trial
findings to other settings; therefore, a question for within person
trials is whether the findings are externally valid to patients with
unilateral disease or who receive the same intervention to both
sites. Bilateral disease can sometimes indicate poorer clinical
status than unilateral disease. For example, diabetic neuropathy
is a systemic consequence of diabetes that is considered worse
if multiple limbs are affected, and the need for multiple dental
implants is indicative of a worse dental condition.
Giving the participant the interventions with a time difference,
eg early and late loaded implants or one hip replacement at a
time, can potentially influence the outcome. The outcome of
the first intervention could affect the outcome of the second
intervention and hence the applicability of the within person
trial findings in other settings. In some cases, however, the
sequential approach is standard clinical practice (eg cataract
surgery).
More complicated trial designs
We have largely discussed reporting of the simple within person
design, where each participant has two sites that receive the two
competing interventions either concurrently or sequentially.
Here we briefly discuss more complicated variations of the
simple within person design.
Asymmetric conditions (multiple lesions)
Some conditions (such as warts, bedsores, leg ulcers, psoriasis,
and dental caries) can occur in multiple sites concurrently. Trials
of such conditions require careful consideration of study design,
with strong implications for data analysis and the presentation
of results.
Study design and treatment allocation—Suppose, for example,
we want to design a randomised trial to see which of two
treatments leads to better outcome for treating lesions of some
sort (eg faster resolution). Participants in a trial are likely to
have a varying numbers of lesions or affected body sites. Several
designs are possible:
1.Include just one lesion per patient either randomly selected
or perhaps the most severe lesion.
Example: Watson et al71 compared high frequency
ultrasonography for up to 12 weeks plus standard care with
standard care alone to treat venous ulcers. The primary
outcome was time to healing of the largest eligible leg
ulcer.
Example: Rajak et al72 compared recurrence of
trachomatous trichiasis in Ethiopia using either absorbable
or silk sutures by randomising only one eye per participant.
Comment: This design avoids potential carry across effect
by turning the trial into a parallel group design but loses
the efficiencies of a within person design.
2.Choose exactly two lesions per patient (disregarding any
additional lesions and patients with only one lesion), at
random or in relation to severity. Select at random which
treatment each lesion will receive and carry out a simple
within person paired analysis.
Example: “The GDPs [general dental practitioners]
recruited children who had caries affecting pairs of primary
molar teeth, which were matched for tooth type, arch, and
extent of caries. Where more than one pair of matched
carious lesions were present in a child’s mouth, the dentist
chose which pair should be part of the study. Any carious
teeth outwith the study were managed as per the dentists’
normal treatment regime.”35
Comment: Turns the design into the simple within person
design covered in this guideline; however site selection
can be a source of bias.
3.Randomise patients to a treatment that is then applied to
all their lesions and consider whether all the lesions
disappeared or not.
Example: “[Participants] were 101 hands (79 patients)
treated in the department. ECTR [endoscopic carpal tunnel
release] was performed in 51 hands (40 patients), and
OCTR [open carpal tunnel release] was performed in 50
hands (39 patients).73
Example: “Fifty one consecutive patients (44 women and
7 men) with unilateral or bilateral hallux valgus gave their
informed consent before entering the trial. The type of
osteotomy for each patient was randomised by the use of
a computer generated list. In bilateral cases, both feet had
the same selected operation during the same operating
session. The Wilson group included 42 feet in 26 patients
(three with rheumatoid arthritis) . . . The chevron group
comprised 45 feet in 25 patients.” 74
Comment: This design is a cluster randomised trial in which
the clusters are the individual participants, and it uses the
maximum potential amount of data. In this design a
combined severity index across all lesions can be calculated
for a patient, such as the total lesion area. This converts
the design into an individually randomised trial.
4.Randomise each lesion separately, possibly using blocking
within patients to make sure that each patient receives both
treatments (patients with just one lesion could be excluded).
Example: Stender et al75 randomised individual warts (1-19
per patient) using blocks of size two within patients.
Comment: This design avoids choosing only some affected
lesions for participants who have many and is similar to a
matched clustered randomised design with variable cluster
size as some patients with more lesions contribute
disproportionately to the overall result. Proper analysis can
downplay the effect of a single patient with multiple lesions
accordingly.
5.Group each patient’s lesions by site, eg by limb or by side
of body, and randomise the sites within patients, so that all
lesions in one site receive the same treatment.
Example: Helsing et al76 compared fractional CO2 laser
assisted photodynamic therapy versus laser alone in 10
organ transplant recipients with a total of 680 actinic
keratosis and 409 wart-like lesions on the dorsal hands.
Comment: This also resembles a matched clustered
randomised design. As for cluster RCTs, including a small
number of patients each with a larger number of lesions is
less desirable than a large number of patients with few
lesions each. Because of intra-individual correlations the
greatest power comes from having more patients with fewer
lesions. Not only is there much less impact of the
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intra-individual correlations, but there is better
generalisability.
6.Within person trials can evaluate more than two treatments
if all included patients have three or more lesions.
Example: “To be included in the study, participants were
required to have at least three radiographically observed
caries proximal lesions in the posterior teeth, with a score
of 3 or 4 in the following modified radiographic scoring
system: 0, no radiolucency; 1, outer half of enamel; 2, inner
half of enamel; 3, around the enamel dentin junction; 4,
outer third of dentin; 5, middle third of dentin; 6, inner
third of dentin; and 7, not assessable. The three lesions
were randomly allocated (in randomly permuted blocks
generated by SPSS) to one of three groups undisclosed to
the participants: A, infiltration; B, sealing; C, placebo.” 77
Comment: This is a three arm trial that allows the
comparison of three treatments using a within person
design.
Analysis—Statistical analysis will also vary according to the
design, using methods appropriate for binary outcomes (eg
disappearance of wart), time to event (eg time to heal), or
continuous outcomes (eg reduction in size of lesion). Multilevel
modelling can be implemented when multiple sites in
participants are analysed.
A common error is to ignore the design and analyse data at the
level of the lesion—that is, to assume that each lesion is from
a different person. This leads to spurious precision. For example,
Stender et al75 randomised individual warts (1-19 per participant)
but analysed the data at the level of the wart not the participant.
For designs with multiple sites the data can be reduced to one
observation per intervention by combining across multiple
lesions. For example, the RECIST criteria78 are used to get an
overall measure of severity for patients with multiple solid
tumours (eg mesothelioma). Another approach is to take for
each patient the proportion of lesions successfully treated (eg
Wiegell et al79). The disadvantages of these approaches include
loss of information and assignment of equal weight to all patients
regardless of the number of affected lesions. Whether treatments
may be less effective for patients with more lesions can be
considered in a subsidiary analysis.
Presentation of results—Authors should report the distribution
of the number of affected lesions across patients separately for
each treatment.
Mixture of participants with unilateral and bilateral
disease
Example—“If both eyes had high risk prethreshold ROP
[retinopathy of prematurity], one eye was randomized to
treatment at the prethreshold level, and the other (the control
eye) was followed and managed conventionally. If the control
eye reached threshold severity of ROP, and this was confirmed
by a second examiner, the eye underwent peripheral retinal
ablation. Otherwise, it was observed. When only one eye had
high risk prethreshold ROP and the fellow eye had milder
disease, a separate randomization scheme assigned such children
with asymmetric ROP to one of the two study groups (early
treatment of the high risk eye versus conventional management
of the high risk eye, with treatment at threshold if needed).
Restricted randomization was performed within each study
center using a block size of 2-6. The exact block size was
unknown to study center personnel. This ensured that after every
block was completed, an equal number of infants with
asymmetric disease would be in each study group. The small
block size was necessary since only 20% of all children within
a study center who meet the criteria for randomization were
expected to have asymmetric disease. If the less severe fellow
eye subsequently progressed, it was managed conventionally.”80
Comment: This design is a mix of a simple parallel design in
which participants with unilateral disease receive a single
treatment selected at random and a within person design in
which the two available sites per individual are randomised to
receive one of two treatments. The unilateral and bilateral
datasets should be analysed separately using methods
appropriate for independent and paired data, respectively. The
two results can be possibly combined using meta-analysis
methods to give an overall effect.81 82
Tables 6 and 7⇓, adapted from the ETROP trial,82 show baseline
data and estimates with associated 95% confidence intervals
separately for the bilateral and unilateral cases. Some of the
included values are fictional.
Comment
Reports of RCTs should include key information on the methods
and findings to allow readers to accurately interpret the results.
Similarly, to enable replication of methods and results requires
complete reporting. 83 This information is particularly important
for meta-analysts attempting to extract data from such reports.
The CONSORT 2010 statement provides the latest
recommendations from the CONSORT group on essential items
to be included in the report of an RCT. We have described an
extension of the CONSORT checklist specific to reporting
within person randomised trials.
Use of the CONSORT statement for the reporting of parallel
trials with two groups is associated with improved reporting
quality.84 85 We think that the routine use of this proposed
extension to the CONSORT statement will eventually result in
similar improvements to within person designs. When reporting
a within person randomised trial, authors should address all
items on the CONSORT checklist using this extension document
in conjunction with the main CONSORT guidelines.2
Depending on the type of trial, authors may also find it useful
to consult the CONSORT extensions for non-pharmacological
treatments7 and non-inferiority11 and cluster randomised trials.10
The CONSORT statement can help researchers to design trials
and can guide peer reviewers and editors in their evaluation of
manuscripts. Many journals recommend adherence to the
CONSORT recommendations in their instructions to authors.
We encourage journals, especially those that publish trials from
the fields of dentistry, dermatology, hand surgery, and
ophthalmology, to direct authors to this and to other extensions
of CONSORT for specific trial designs. The most up to date
versions of all CONSORT recommendations can be found at
www.consort-statement.org.
We thank Barbara Hawkins for her contribution to the early drafts of this
paper.
Contributors: DGA, DE, RWS and Barbara Hawkins initiated the work.
NP, BC, RWS, DE and DGA drafted the manuscript and all authors
reviewed it and approved the final version. DGA is the guarantor.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no
support from any organisation for the submitted work; no financial
relationships with any organisations that might have an interest in the
submitted work in the previous three years; no other relationships or
activities that could appear to have influenced the submitted work.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;357:j2835 doi: 10.1136/bmj.j2835 (Published 2017 June 30) Page 10 of 22
RESEARCH METHODS & REPORTING
1 Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. PLoS Med 2010;357:e1000251.
doi:10.1371/journal.pmed.1000251 pmid:20352064.
2 Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration:
updated guidelines for reporting parallel group randomised trials. BMJ 2010;357:c869.
doi:10.1136/bmj.c869 pmid:20332511.
3 Hopewell S, Clarke M, Moher D, et al. CONSORT Group. CONSORT for reporting
randomised trials in journal and conference abstracts. Lancet 2008;357:281-3. doi:10.
1016/S0140-6736(07)61835-2 pmid:18221781.
4 MacPherson H, Altman DG, Hammerschlag R, et al. STRICTA Revision Group. Revised
STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA):
extending the CONSORT statement. PLoS Med 2010;357:e1000261. doi:10.1371/journal.
pmed.1000261 pmid:20543992.
5 Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. CONSORT Group.
Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT
statement. Ann Intern Med 2006;357:364-7. doi:10.7326/0003-4819-144-5-200603070-
00013 pmid:16520478.
6 Zwarenstein M, Treweek S, Gagnier JJ, et al. CONSORT group Pragmatic Trials in
Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of
the CONSORT statement. BMJ 2008;357:a2390. doi:10.1136/bmj.a2390 pmid:19001484.
7 Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Group. CONSORT
Statement for randomized trials of nonpharmacologic treatments: a 2017 update and a
CONSORT extension for nonpharmacologic trial. Ann Intern Med 2017, doi:10.7326/M17-
0046.
8 Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. CONSORT PRO
Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO
extension. JAMA 2013;357:814-22. doi:10.1001/jama.2013.879 pmid:23443445.
9 Ioannidis JPA, Evans SJW, Gøtzsche PC, et al. CONSORT Group. Better reporting of
harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med
2004;357:781-8. doi:10.7326/0003-4819-141-10-200411160-00009 pmid:15545678.
10 Campbell MK, Piaggio G, Elbourne DR, Altman DG. CONSORT Group. Consort 2010
statement: extension to cluster randomised trials. BMJ 2012;357:e5661. doi:10.1136/bmj.
e5661 pmid:22951546.
11 Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. CONSORT Group. Reporting
of noninferiority and equivalence randomized trials: extension of the CONSORT 2010
statement. JAMA 2012;357:2594-604. doi:10.1001/jama.2012.87802 pmid:23268518.
12 Shamseer L, Sampson M, Bukutu C, et al. CENT Group. CONSORT extension for reporting
N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ 2015;357:h1793. doi:10.
1136/bmj.h1793 pmid:25976162.
13 Paré A. (1575) The James Lind Library. http://www.jameslindlibrary.org/pare-a-1575/
(accessed 29 Sep2016).
14 Piltz J, Gross R, Shin DH, et al. Contralateral effect of topical beta-adrenergic antagonists
in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol
2000;357:441-53. doi:10.1016/S0002-9394(00)00527-4 pmid:11024416.
15 Lesaffre E, Philstrom B, Needleman I, Worthington H. The design and analysis of
split-mouth studies: what statisticians and clinicians should know. Stat Med
2009;357:3470-82. doi:10.1002/sim.3634 pmid:19536744.
16 Pandis N, Walsh T, Polychronopoulou A, Katsaros C, Eliades T. Split-mouth designs in
orthodontics: an overview with applications to orthodontic clinical trials. Eur J Orthod
2013;357:783-9. doi:10.1093/ejo/cjs108 pmid:23376899.
17 Lie SA, Engesaeter LB, Havelin LI, Gjessing HK, Vollset SE. Dependency issues in survival
analyses of 55,782 primary hip replacements from 47,355 patients. Stat Med
2004;357:3227-40.. doi:10.1002/sim.1905 pmid:15449328.
18 Chan A-W, Altman DG. Epidemiology and reporting of randomised trials published in
PubMed journals. Lancet 2005;357:1159-62. doi:10.1016/S0140-6736(05)71879-1 pmid:
15794971.
19 Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised
trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ
2010;357:c723. doi:10.1136/bmj.c723 pmid:20332510.
20 Koletsi D, Fleming PS, Seehra J, Bagos PG, Pandis N. Are sample sizes clear and justified
in RCTs published in dental journals?PLoS One 2014;357:e85949.. doi:10.1371/journal.
pone.0085949 pmid:24465806.
21 Cairo F, Sanz I, Matesanz P, Nieri M, Pagliaro U. Quality of reporting of randomized
clinical trials in implant dentistry. A systematic review on critical aspects in design, outcome
assessment and clinical relevance. J Clin Periodontol 2012;357(Suppl 12):81-107.. doi:
10.1111/j.1600-051X.2011.01839.x pmid:22533949.
22 Lee CF, Cheng ACO, Fong DYT. Eyes or subjects: are ophthalmic randomized controlled
trials properly designed and analyzed?Ophthalmology 2012;357:869-72.. doi:10.1016/j.
ophtha.2011.09.025 pmid:22226885.
23 Lesaffre E, Garcia Zattera M-J, Redmond C, Huber H, Needleman I. ISCB Subcommittee
on Dentistry. Reported methodological quality of split-mouth studies. J Clin Periodontol
2007;357:756-61.. doi:10.1111/j.1600-051X.2007.01118.x pmid:17716311.
24 Scherer RW, Breck J, Ervin A-M. US Cochrane Eyes and Vision Group. Characteristics
of randomized trials in ophthalmology using a within-person paired design. Invest
Ophthalmol Vis Sci 2012;357:4734.
25 Lai TYY, Wong VWY, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of
key methodological items of randomized controlled trials in clinical ophthalmic journals.
Ophthalmic Epidemiol 2007;357:390-8.. doi:10.1080/09286580701344399 pmid:18161613.
26 Bryant D, Havey TC, Roberts R, Guyatt G. How many patients? How many limbs? Analysis
of patients or limbs in the orthopaedic literature: a systematic review. J Bone Joint Surg
Am 2006;357:41-5. doi:10.2106/JBJS.E.00272. pmid:16391248.
27 Karakosta A, Vassilaki M, Plainis S, Elfadl NH, Tsilimbaris M, Moschandreas J. Choice
of analytic approach for eye-specific outcomes: one eye or two?Am J Ophthalmol
2012;357:571-579.e1. doi:10.1016/j.ajo.2011.08.032 pmid:22078901.
28 Page MJ, McKenzie JE, Forbes A. Many scenarios exist for selective inclusion and
reporting of results in randomized trials and systematic reviews. J Clin Epidemiol
2013;357:524-37.. doi:10.1016/j.jclinepi.2012.10.010 pmid:23337785.
29 Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research
reporting guidelines. PLoS Med 2010;357:e1000217.. doi:10.1371/journal.pmed.
1000217 pmid:20169112.
30 Waddell KM, Reeves BC, Johnson GJ. A comparison of anterior and posterior chamber
lenses after cataract extraction in rural Africa: a within patient randomised trial. Br J
Ophthalmol 2004;357:734-9. doi:10.1136/bjo.2003.031187 pmid:15148202.
31 Haraji A, Rakhshan V, Khamverdi N, Alishahi HK. Effects of intra-alveolar placement of
0.2% chlorhexidine bioadhesive gel on dry socket incidence and postsurgical pain: a
double-blind split-mouth randomized controlled clinical trial. J Orofac Pain 2013;357:256-62.
doi:10.11607/jop.1142 pmid:23882458.
32 Weiss R, Bank D, Brandt D. Randomized, double-blind, split-face study of small-gel-particle
hyaluronic acid with and without lidocaine during correction of nasolabial folds. Dermatol
Surg 2010;357:750-9doi:10.1111/j.1524-4725.2010.01547.x.
33 Chayet A, Bains HS. Prospective, randomized, double-blind, contralateral eye comparison
of myopic LASIK with optimized aspheric or prolate ablations. J Refract Surg
2012;357:112-9.. doi:10.3928/1081597X-20111219-01 pmid:22201324.
34 Hütz WW, Jäckel R, Hoffman PC. Comparison of visual performance of silicone and
acrylic multifocal IOLs utilizing the same diffractive design. Acta Ophthalmol
2012;357:530-3.. doi:10.1111/j.1755-3768.2010.01984.x pmid:20716324.
35 Innes NP, Evans DJP, Stirrups DR. The Hall Technique; a randomized controlled clinical
trial of a novel method of managing carious primary molars in general dental practice:
acceptability of the technique and outcomes at 23 months. BMC Oral Health 2007;357:18..
doi:10.1186/1472-6831-7-18 pmid:18096042.
36 Nanavaty MA, Spalton DJ, Gala KB, Dhital A, Boyce J. Fellow-eye comparison of posterior
capsule opacification between 2 aspheric microincision intraocular lenses. J Cataract
Refract Surg 2013;357:705-11.. doi:10.1016/j.jcrs.2012.12.030 pmid:23608567.
37 Welch MN, Czyz CN, Kalwerisky K, Holck DE, Mihora LD. Double-blind, bilateral pain
comparison with simultaneous injection of 2% lidocaine versus buffered 2% lidocaine for
periocular anesthesia. Ophthalmology 2012;357:2048-52.. doi:10.1016/j.ophtha.2012.05.
029 pmid:22771049.
38 Leydolt C, Schriefl S, Stifter E, Haszcz A, Menapace R. Posterior capsule opacification
with the iMics1 NY-60 and AcrySof SN60WF 1-piece hydrophobic acrylic intraocular
lenses: 3-year results of a randomized trial. Am J Ophthalmol 2013;357:375-381.e2.. doi:
10.1016/j.ajo.2013.04.007 pmid:23677137.
39 Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template
for intervention description and replication (TIDieR) checklist and guide. BMJ
2014;357:g1687. doi:10.1136/bmj.g1687 pmid:24609605.
40 Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl
aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to
conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled
trial. Br J Dermatol 2014;357:1164-71.. doi:10.1111/bjd.13138 pmid:24861492.
41 Wheelock ME, Leblanc M, Chung B, Williams J, Lalonde DH. Is it true that injecting palmar
finger skin hurts more than dorsal skin? New level 1 evidence. Hand (N Y) 2011;357:47-9..
doi:10.1007/s11552-010-9288-2 pmid:22379437.
42 Wang MTM, Jaitley Z, Lord SM, Craig JP. Comparison of Self-applied Heat Therapy for
Meibomian Gland Dysfunction. Optom Vis Sci 2015;357:e321-6.. doi:10.1097/OPX.
0000000000000601 pmid:25955642.
43 Ebenbichler GR, Resch KL, Nicolakis P, et al. Ultrasound treatment for treating the carpal
tunnel syndrome: randomised “sham” controlled trial. BMJ 1998;357:731-5. doi:10.1136/
bmj.316.7133.731 pmid:9529407.
44 Smaïl-Faugeron V, Muller-Bolla M, Sixou J-L, Courson F. Split-mouth and parallel-arm
trials to compare pain with intraosseous anaesthesia delivered by the computerised
Quicksleeper system and conventional infiltration anaesthesia in paediatric oral healthcare:
protocol for a randomised controlled trial. BMJ Open 2015;357:e007724.. doi:10.1136/
bmjopen-2015-007724 pmid:26163031.
45 Wang D, Bakhai A. Chapter 10. Clinical Trials in Practice. A Practical Guide to Design,
Analysis and Reporting. Remedica, 2006.
46 Katz J. Two eyes or one? The data analyst’s dilemma. Ophthalmic Surg
1988;357:585-9.pmid:3173980.
47 van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding
laser and photoepilation therapy alone). Cochrane Database Syst Rev
2015;357:CD010334. doi:10.1002/14651858.CD010334.pub2. pmid:25918921.
48 Pandis N, Fleming PS, Spineli LM, Salanti G. Initial orthodontic alignment effectiveness
with self-ligating and conventional appliances: a network meta-analysis in practice. Am
J Orthod Dentofacial Orthop 2014;357(Suppl):S152-63.. doi:10.1016/j.ajodo.2013.12.
016 pmid:24680024.
49 Balk EM, Earley A, Patel K, Trikalinos TA, Dahabreh IJ. Empirical Assessment of
Within-Arm Correlation Imputation in Trials of Continuous Outcomes. Methods Research
Report. (Prepared by the Tufts Evidence-based Practice Center under Contract No.
290-2007-10055-I.) AHRQ Publication No. 12(13)-EHC141-EF. Rockville, MD: Agency
for Healthcare Research and Quality. November 2012.
50 Julious SA, Campbell MJ, Altman DG. Estimating sample sizes for continuous, binary,
and ordinal outcomes in paired comparisons: practical hints. J Biopharm Stat
1999;357:241-51.. doi:10.1081/BIP-100101174 pmid:10379691.
51 Vasavada VA, Praveen MR, Shah SK, Trivedi RH, Vasavada AR. Anti-inflammatory effect
of low-molecular-weight heparin in pediatric cataract surgery: a randomized clinical trial.
Am J Ophthalmol 2012;357:252-258.e4.. doi:10.1016/j.ajo.2012.02.021 pmid:22541652.
52 Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic
factors in the controlled clinical trial. Biometrics 1975;357:103-15. doi:10.2307/
2529712 pmid:1100130.
53 Hayashi K, Tsuru T, Yoshida M, Hirata A. Intraocular pressure and wound status in eyes
immediately after scleral tunnel incision and clear corneal incision cataract surgery. Am
J Ophthalmol 2014;357:232-41.. doi:10.1016/j.ajo.2014.04.018 pmid:24792102.
54 Yu KCY, Nettar KD, Bapna S, Boscardin WJ, Maas CS. Split-face double-blind study
comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial
Plast Surg 2012;357:198-204.. doi:10.1001/archfacial.2011.1142 pmid:22183059.
55 Bonaparte JP, Javidnia H, Kilty S. A double-blind randomised controlled trial assessing
the efficacy of topical lidocaine in extended flexible endoscopic nasal examinations. Clin
Otolaryngol 2011;357:550-7.. doi:10.1111/j.1749-4486.2011.02403.x pmid:22017968.
56  ICMJE. http://www.icmje.org/recommendations/browse/manuscript-preparation/preparing-
for-submission.html#d.
57 Bland JM, Altman DG. Comparisons against baseline within randomised groups are often
used and can be highly misleading. Trials 2011;357:264.. doi:10.1186/1745-6215-12-
264 pmid:22192231.
58 He L, Manche EE. Contralateral eye-to-eye comparison of wavefront-guided and
wavefront-optimized photorefractive keratectomy: a randomized clinical trial. JAMA
Ophthalmol 2015;357:51-9.. doi:10.1001/jamaophthalmol.2014.3876 pmid:25321951.
59 Dennis DA, Heekin RD, Clark CR, Murphy JA, O’Dell TL, Dwyer KA. Effect of implant
design on knee flexion. J Arthroplasty 2013;357:429-38.. doi:10.1016/j.arth.2012.07.
019 pmid:23219622.
60 Song BH, Lee DH, Kim BC, et al. Photodynamic therapy using chlorophyll-a in the
treatment of acne vulgaris: a randomized, single-blind, split-face study. J Am Acad
Dermatol 2014;357:764-71.. doi:10.1016/j.jaad.2014.05.047 pmid:24930587.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;357:j2835 doi: 10.1136/bmj.j2835 (Published 2017 June 30) Page 11 of 22
RESEARCH METHODS & REPORTING
61 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions
of methodological quality associated with estimates of treatment effects in controlled trials.
JAMA 1995;357:408-12. doi:10.1001/jama.1995.03520290060030 pmid:7823387.
62 Fischer TJ. Orthodontic treatment acceleration with corticotomy-assisted exposure of
palatally impacted canines. Angle Orthod 2007;357:417-20.. doi:10.2319/0003-3219(
2007)077[0417:OTAWCE]2.0.CO;2 pmid:17465647.
63 Innes NPT, Evans DJP, Stirrups DR. Sealing caries in primary molars: randomized control
trial, 5-year results. J Dent Res 2011;357:1405-10.. doi:10.1177/0022034511422064 pmid:
21921249.
64 Stedman MR, Curtin F, Elbourne DR, Kesselheim AS, Brookhart MA. Meta-analyses
involving cross-over trials: methodological issues. Int J Epidemiol 2011;357:1732-4.. doi:
10.1093/ije/dyp345 pmid:20026595.
65 Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical
trials. II: Binary outcomes. Stat Med 2002;357:2145-59.. doi:10.1002/sim.1206 pmid:
12210630.
66 Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses
involving cross-over trials: methodological issues. Int J Epidemiol 2002;357:140-9. doi:
10.1093/ije/31.1.140 pmid:11914310.
67 Gonzalez P, Vila R, Cirigliano M. The tolerability profile of clindamycin 1%/benzoyl peroxide
5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a
randomized, single-blind, split-face study. J Cosmet Dermatol 2012;357:251-60.. doi:10.
1111/jocd.12013 pmid:23174047.
68 Kearney C, Brew D. Single-session combination treatment with intense pulsed light and
nonablative fractional photothermolysis: a split-face study. Dermatol Surg
2012;357:1002-9.. doi:10.1111/j.1524-4725.2012.02401.x pmid:22574965.
69 Bhattacharya R, Birdsall PD, Finn P, Stothard J. A randomized controlled trial of knifelight
and open carpal tunnel release. J Hand Surg Br 2004;357:113-5.. doi:10.1016/j.jhsb.2003.
09.001 pmid:15010154.
70 Malecaze FJ, Hulin H, Bierer P, et al. A randomized paired eye comparison of two
techniques for treating moderately high myopia: LASIK and artisan phakic lens.
Ophthalmology 2002;357:1622-30. doi:10.1016/S0161-6420(02)01164-8 pmid:12208708.
71 Watson JM, Kang’ombe AR, Soares MO, et al. VenUS III Team. Use of weekly, low dose,
high frequency ultrasound for hard to heal venous leg ulcers: the VenUS III randomised
controlled trial. BMJ 2011;357:d1092. doi:10.1136/bmj.d1092 pmid:21385806.
72 Rajak SN, Habtamu E, Weiss HA, et al. Absorbable versus silk sutures for surgical
treatment of trachomatous trichiasis in Ethiopia: a randomised controlled trial. PLoS Med
2011;357:e1001137.. doi:10.1371/journal.pmed.1001137 pmid:22180732.
73 Ejiri S, Kikuchi S, Maruya M, Sekiguchi Y, Kawakami R, Konno S. Short-term results of
endoscopic (Okutsu method) versus palmar incision open carpal tunnel release: a
prospective randomized controlled trial. Fukushima J Med Sci 2012;357:49-59. doi:10.
5387/fms.58.49 pmid:22790892.
74 Klosok JK, Pring DJ, Jessop JH, Maffulli N. Chevron or Wilson metatarsal osteotomy for
hallux valgus. A prospective randomised trial. J Bone Joint Surg Br 1993;357:825-9.pmid:
8376450.
75 Stender IM, Na R, Fogh H, Gluud C, Wulf HC. Photodynamic therapy with 5-aminolaevulinic
acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet
2000;357:963-6.. doi:10.1016/S0140-6736(00)90013-8 pmid:10768434.
76 Helsing P, Togsverd-Bo K, Veierød MB, Mørk G, Haedersdal M. Intensified fractional
CO2 laser-assisted photodynamic therapy vs. laser alone for organ transplant recipients
with multiple actinic keratoses and wart-like lesions: a randomized half-side comparative
trial on dorsal hands. Br J Dermatol 2013;357:1087-92.. doi:10.1111/bjd.12507 pmid:
23855503.
77 Martignon S, Ekstrand KR, Gomez J, Lara JS, Cortes A. Infiltrating/sealing proximal caries
lesions: a 3-year randomized clinical trial. J Dent Res 2012;357:288-92.. doi:10.1177/
0022034511435328 pmid:22257664.
78 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;357:228-47.. doi:
10.1016/j.ejca.2008.10.026 pmid:19097774.
79 Wiegell SR, Fabricius S, Gniadecka M, et al. Daylight-mediated photodynamic therapy
of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre
study. Br J Dermatol 2012;357:1327-32.. doi:10.1111/j.1365-2133.2012.10833.x pmid:
22250644.
80 Hardy RJ, Good WV, Dobson V, et al. Early Treatment for Retinopathy of Prematurity
Cooperative Group. Multicenter trial of early treatment for retinopathy of prematurity: study
design. Control Clin Trials 2004;357:311-25.. doi:10.1016/j.cct.2004.03.003 pmid:
15157731.
81 Esposito M, Maghaireh H, Grusovin MG, Ziounas I, Worthington HV. Interventions for
replacing missing teeth: management of soft tissues for dental implants. Cochrane
Database Syst Rev 2012;357:CD006697. doi:10.1002/14651858.CD006697.pub2. pmid:
22336822.
82  Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy
RJ, et al.Final visual acuity results in the early treatment for retinopathy of prematurity
study. Arch Ophthalmol Chic Ill 1960;357:663-71. doi:10.1001/archophthalmol.2010.72.
83 Goodman SN, Fanelli D, Ioannidis JPA. What does research reproducibility mean?Sci
Transl Med 2016;357:341ps12. doi:10.1126/scitranslmed.aaf5027 pmid:27252173.
84 Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT
Statement impact the completeness of reporting of randomised controlled trials published
in medical journals? A Cochrane review. Syst Rev 2012;357:60.. doi:10.1186/2046-4053-
1-60 pmid:23194585.
85 Pandis N, Shamseer L, Kokich VG, Fleming PS, Moher D. Active implementation strategy
of CONSORT adherence by a dental specialty journal improved randomized clinical trial
reporting. J Clin Epidemiol 2014;357:1044-8. doi:10.1016/j.jclinepi.2014.04.001 pmid:
24837296.
Accepted: 13 05 2017
Published by the BMJ Publishing Group Limited. For permission to use (where not already
granted under a licence) please go to http://group.bmj.com/group/rights-licensing/
permissions
This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,
remix, adapt, build upon this work non-commercially, and license their derivative works
on different terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;357:j2835 doi: 10.1136/bmj.j2835 (Published 2017 June 30) Page 12 of 22
RESEARCH METHODS & REPORTING
Tables
Table 1| Information to include in the abstract of a report of a within person randomised trial: extension of CONSORT for abstracts checklist
Extension for within person trialsStandard CONSORT checklist item3Item
Identification of study as a within person trial (or an
alternative accepted term in the specialty)
Identification of study as randomisedTitle
Description of the trial design (eg parallel, cluster, non-inferiority)Trial design
Methods:
Eligibility criteria for body sitesEligibility criteria for participants and the settings where the data were collected  Participants
Intervention timing: sequential or concurrentInterventions intended for each group  Interventions
Specific objective or hypothesis  Objective
Clearly defined primary outcome for this report  Outcome
How body sites were allocated within a single participantHow participants were allocated to interventions  Randomisation
Whether or not participants, care givers, and those assessing the outcomes were
blinded to group assignment
  Blinding(masking)
Results:
Number of body sites randomised to each groupNumber of participants randomised to each group  Numbers randomised
Trial status  Recruitment
Number of body sites analysed in each groupNumber of participants analysed in each group  Numbers analysed
For the primary outcome, a result for each group and the estimated effect size
and its precision
  Outcome
For participants and for body sitesImportant adverse events or side effects  Harms
General interpretation of the resultsConclusions
Registration number and name of trial registerTrial registration
Source of fundingFunding
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Table 2| Demographic and baseline data of the participants. Adapted from Song et al60
n (%) unless otherwise specifiedParticipant characteristics
23.4 (3.5)Age (years)*
Sex:
14 (58.3%)  Male
10 (41.7%)  Female
Fitzpatrick skin type:
12 (50%)  III
12 (50%)  IV
Phototherapy only sideChlorophyll-PDT sideAcne severity (baseline):
4 (16.7%)3 (12.5%)  Grade 2
14 (58.3%)15 (62.5%)  Grade 3
6 (25.0%)6 (25.0%)  Grade 4
PDT=Photodynamic therapy
*Figures are mean (standard deviation)
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Table 3| Display of correlation coefficient, adapted from Fischer et al62
CorrelationExposure
0.70Conventional and corticotomy
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Table 4| Matched tabulation of outcomes with two interventions, modified from Innes et al63
Control restoration*
Odds ratio (95% CI)TotalNo major failureMajor failureHall technique (all teeth with follow-up data)
0.06 (0.001 to 0.375)†
Favours half technique
514Major failure
12310617No major failure
12810721Total
*(All teeth with follow-up data)
†The cell counts have been adjusted by adding 1 to each cell to allow calculation of the odds ratio and the 95% confidence interval
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Table 5| Matched pair tabulation for binary results
Treatment B
TotalFailureSuccessTreatment A
a=s+ttsSuccess
c=u+vvuFailure
n=a+b+c+dd=t+vb=s+uTotal
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Table 6| Distribution of eyes and participants with unilateral and bilateral retinopathy prematurity across treatment arms, adapted from the
ETROP trial82
TotalConventional treatment of retinopathy prematurityEarlier treatment of retinopathy prematurity
Bilateral
317 participants (634 eyes)317317n
Gender:
155 (48.9%)155 (48.9%)  Male
162 (51.1%)162 (51.1%)  Female
6.1 months6.1 monthsAge
12.112.1Visual Acuity
Unilateral
84 participants (84 eyes)4242n
Gender
22(52.4%)20 (47.6%)Male
20(47.6%)22 (52.4%)Female
6.0 months5.9 monthsAge
12.012.3Visual acuity
Note that the table includes some fictional data.
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Table 7| Estimates and associated 95% confidence intervals separately for the bilateral and unilateral cases. The table has been constructed
using the ETROP trial data82
P valueOdds ratio (95% CI)Risk difference (95% CI)Events/n (%)
      Conventionally managed eyes      Eyes treated at high risk prethreshold
0.370.84 (0.57 to 1.24)−3.7% (−0.12 to 0.04)75/247 (30.4)66/247 (26.7)Bilateral
0.340.48 (0.11 to 2.03)−8.1% (−0.25 to 0.09)5/29 (17.2)3/33 (9.1)Unilateral
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Figures
Fig 1 Extension to CONSORT 2010 checklist for reporting within person randomised trials. For within person trials, a group
is the set of participants’ body sites that was allocated a particular intervention.
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Fig 2 The abstract on the left is as published.30 The abstract on the right has been amended to comply with the minimum
reporting requirements for abstracts shown in table 1⇓, combining the standard checklist item with the extension for within
person trials. Added text is shown in red.
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Fig 3 Flow diagram adapted from He and Manche58
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